Automated real-time needle-guide tracking for fast 3-T MR-guided transrectal prostate biopsy: A feasibility study

Radiology

Volumn 273, Issue 3, 2014, Pages 879-886

  Zamecnik, Patrik ^a   Schouten, Martijn G ^a   Krafft, Axel J ^b   Maier, Florian ^c   Schlemmer, Heinz Peter ^d   Barentsz, Jelle O ^a   Bock, Michael ^e   Fütterer, Jurgen J ^a,f  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; CONTRAST MEDIUM; GADOTERATE MEGLUMINE; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ALGORITHM; ARTICLE; AUTOMATION; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEASIBILITY STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFORMED CONSENT; MALE; NEEDLE GUIDE TRACKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE ONLY CROSS CORRELATION ALGORITHM; PROSTATE BIOPSY; PROSTATE CANCER; REAL TIME TRACKING SYSTEM; TRANSRECTAL ULTRASONOGRAPHY; DIAGNOSTIC USE; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PROSTATE TUMOR; RECTUM; TIME;

AGED; ALGORITHMS; AUTOMATION; BIOPSY, NEEDLE; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PROSTATIC NEOPLASMS; RECTUM; TIME FACTORS;

EID: 84916629411     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14132067     Document Type: Article

References (24)

1. Halpern EJ, Strup SE. Using gray-scale and color and power Doppler sonography to detect prostatic cancer. AJR Am J Roentgenol 2000;174(3):623-627
2. Terris MK. Sensitivity and specificity of sextant biopsies in the detection of prostate cancer: preliminary report. Urology 1999;54(3):486-489
3. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998;159(4):1247-1250
4. Mian BM, Naya Y, Okihara K, Vakar-Lopez F, Troncoso P, Babaian RJ. Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology 2002;60(5):836-840
5. Philip J, Hanchanale V, Foster CS, Javlé P. Importance of peripheral biopsies in maximising the detection of early prostate cancer in repeat 12-core biopsy protocols. BJU Int 2006;98(3):559-562
6. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002;167(6):2435-2439
7. Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011;261(1):46-66
8. Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010;183(2):520-527
9. Anastasiadis AG, Lichy MP, Nagele U, et al. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 2006;50(4):738-748; discussion 748-749
10. Beyersdorff D, Winkel A, Hamm B, Lenk S, Loening SA, Taupitz M. MR imaging- guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology 2005;234(2):576-581
11. Pondman KM, Fütterer JJ, ten Haken B, et al. MR-guided biopsy of the prostate: An overview of techniques and a systematic review. Eur Urol 2008;54(3):517-527
12. Zangos S, Melzer A, Eichler K, et al. MRcompatible assistance system for biopsy in a high-field-strength system: initial results in patients with suspicious prostate lesions. Radiology 2011;259(3):903-910
13. de Oliveira A, Rauschenberg J, Beyersdorff D, Semmler W, Bock M. Automatic passive tracking of an endorectal prostate biopsy device using phase-only cross-correlation. Magn Reson Med 2008;59(5):1043-1050
14. Maier F, Krafft AJ, Stafford AJ, et al. 3D passive marker tracking for MR-guided interventions [abstr]. In: Proceedings of the Nineteenth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2011; 3749
15. Krafft AJ, Zamecnik P, Maier F, et al. Passive marker tracking via phase-only cross correlation (POCC) for MR-guided needle interventions: initial in vivo experience. Phys Med 2013;29(6):607-614
16. Huisman HJ, Engelbrecht MR, Barentsz JO. Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging 2001;13(4):607-614
17. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10(3):223-232
18. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22(4):746-757
19. Nagel KN, Schouten MG, Hambrock T, et al. Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology 2013;267(1):164-172
20. Roethke M, Anastasiadis AG, Lichy M, et al. MRI-guided prostate biopsy detects clinically significant cancer: Analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2012;30(2): 213-218
21. Bomers JG, Sedelaar JP, Barentsz JO, Fütterer JJ. MRI-guided interventions for the treatment of prostate cancer. AJR Am J Roentgenol 2012;199(4):714-720
22. Gangi A, Tsoumakidou G, Abdelli O, et al. Percutaneous MR-guided cryoablation of prostate cancer: initial experience. Eur Radiol 2012;22(8):1829-1835
23. Hadaschik BA, Kuru TH, Tulea C, et al. A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J Urol 2011;186(6): 2214-2220
24. Roethke MC, Kuru TH, Schultze S, et al. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion- guided biopsy at 3.0 Tesla. Eur Radiol 2014;24(2):344-352